drugset / Trial / NCT00701363

Study to Assess the Efficacy of an Extended Injection Interval Schedule of Lanreotide Autogel in Acromegalic Subjects

NCT00701363

Phase 4 Completed 124 enrolled Ipsen
NaSingle-groupOpen-labelTreatment

Summary

The purpose of the study is to assess the efficacy of an extended injection interval schedule of lanreotide Autogel 120 mg in acromegalic subjects who are biochemically controlled on long term treatment with octreotide LAR 10 or 20 mg

Timeline

Start
2008-10
Primary completion
2013-03
Completion
2013-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Lanreotide Other / unclassified 120 mg

Indications